ZIJIN GOLD INTL(02259.HK) closed 7.6% higher, the latest market capitalization at HKD 431.96 billion
NewTimeSpace News: By the close of trading on May 6, 2026, ZIJIN GOLD INTL(02259.HK) saw a gain of 7.6% in its share price, closing at HKD 161.4. During the session, it reached an intraday high of HKD 162.9 and touched an intraday low of HKD 148.7. The full-day turnover stood at HKD 1.2 billion, with the latest market capitalization at HKD 431.96 billion.
On the sector front, the Hang Seng Gold & Precious Metals Sector, to which ZIJIN GOLD INTL belongs, showed an overall broad gains trend, with 13 stocks advancing and 1 stocks declining.Among the gainers, CHIFENG GOLD closed higher by 11.14%, LINGBAO GOLD closed higher by 8.21%, WANGUO GOLD GP closed higher by 7.62%, ZIJIN GOLD INTL closed higher by 7.6%, SD GOLD closed higher by 7.32%.Among the decliners, LOCO HK closed lower by 3.03%.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ZIJIN GOLD INTL(02259.HK)2026 Interim Report - Profit Attributable to Shareholders stood at USD 1.45 billion, YoY increase of 178.83%
- Zijin Mining (02899.HK)/Zijin Gold International (02259.HK): Terminates Allied Gold Takeover, Switches to CAD416.6 Million Subscription for 9.2% Sta
- ZIJIN GOLD INTL(02259.HK): Expected Net Profit of Approximately USD1.4 Billion for H1 2026, Surge of Around 169% YoY
- ZIJIN GOLD INTL(02259.HK) closed 15.06% higher on Jun 15, leading gains in the Hang Seng Gold & Precious Metals Sector
- CanSino Biologics (06185.HK): NDA for Td5cp, a Diphtheria-Tetanus-Pertussis Vaccine for Adolescents and Adults, Accepted for Review